The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT-EHA CAR-T 2019 | CAR-T19: A novel model of recognition
Jürgen Kuball MD, PhD, from the University Medical Center, Utrecht, Amsterdam, discusses the mode of recognition of T-cells engineered to express γδT cell receptor (TEGs), and the way in which this receptor (γδT) allows for the recognition of cancer cells via there early metabolic changes. Recorded at the 1st European CAR T-Cell Meeting in Paris, France, co-organized by the European Society for Blood & Marrow Transplantation (EBMT) and the European Hematology Association (EHA).
